Aligning CMC And MSAT To Move PATs Out Of Pilot Mode

Process analytical technologies (PATs) seem to be suspended in a purgatory of promise. They are powerful tools, but PATs can often stall in the transition from concept to scale. One persistent and under-appreciated hurdle stunting their progress is the disconnect between process development (CMC) and manufacturing (MSAT) teams. Despite having a shared interest in product quality and process efficiency, these teams operate under different priorities and on different timelines. This misalignment keeps PATs in pilot mode, limiting their impact and ROI.

In this on-demand event, CMC and MSAT experts Yanhuai (Richard) Ding, Ph.D., senior director of CMC at EvolveImmune Therapeutics; Thomas Kowski, VP of analytical development at Umoja Biopharma; Mengyao Li, Ph.D., principal scientist at Novartis; and Luc Nguyen, Ph.D., head of MSAT for vaccines at Sanofi, discuss how companies can align their teams to overcome internal barriers and unlock the promise of PATs. This Bioprocess Online Live event was hosted by Tyler Menichiello and is free to watch thanks to the event sponsor, Greenfield Global.